The Wnt/β-catenin pathway in ovarian cancer: a review.

OBJECTIVE Ovarian cancer is the deadliest gynecologic malignancy and the fifth leading cause of death from cancer in women in the U.S. Since overall survival remains poor, there is a need for new therapeutic paradigms. This paper will review the Wnt/β-catenin pathway as it relates to epithelial ovarian cancer, specifically its role in chemoresistance and its potential role as a target for chemosensitization. METHODS A PubMed search was performed for articles published pertaining to Wnt/β-catenin pathway specific to ovarian cancer. Wnt/β-catenin signaling pathways play an active role in cancer stem cells (CSCs) and carcinogenesis of all ovarian cancer subtypes. Studies also have shown that ovarian CSCs are involved in chemoresistance, metastasis, and tumor recurrence. RESULTS Wnt/β-catenin target genes regulate cell proliferation and apoptosis, thereby mediating cancer initiation and progression. The Wnt/β-catenin pathway is one of the major signaling pathways thought to be involved in epithelial-to-mesenchymal transition (EMT). Alterations affecting Wnt pathway proteins on the cell membrane, in the cytoplasm, and in the nucleus have been shown to play important roles in the tumorigenesis of ovarian cancer. CONCLUSIONS Wnt signaling is activated in epithelial ovarian cancer. Given the role of the Wnt/β-catenin pathway in carcinogenesis, more pre-clinical studies are warranted to further investigate other Wnt inhibitors in ovarian cancer. The Wnt pathway should also be investigated as a potential target in the development of new drugs for ovarian cancer as a single agent and in combination with chemotherapy or other targeted agents.

[1]  H. Dinh,et al.  A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. , 2012, Cancer research.

[2]  Michael Kahn,et al.  Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells? , 2010, Clinical Cancer Research.

[3]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[4]  B. Gumbiner,et al.  E-Cadherin Suppresses Cellular Transformation by Inhibiting β-Catenin Signaling in an Adhesion-Independent Manner , 2001, The Journal of cell biology.

[5]  A. Boyer,et al.  WNT signaling in ovarian follicle biology and tumorigenesis , 2010, Trends in Endocrinology & Metabolism.

[6]  Zijie Sun,et al.  Roles and regulation of Wnt signaling and β-catenin in prostate cancer , 2006 .

[7]  P. Harris,et al.  Targeting embryonic signaling pathways in cancer therapy , 2012, Expert opinion on therapeutic targets.

[8]  J. Nesland,et al.  Adenomatous Polyposis Coli (APC) Protein Expression in Primary and Metastatic Serous Ovarian Carcinoma , 2002, International journal of surgical pathology.

[9]  Yoshihiro Nishioka,et al.  Mutational Analysis of β‐Catenin Gene in Japanese Ovarian Carcinomas: Frequent Mutations in Endometrioid Carcinomas , 1999, Japanese journal of cancer research : Gann.

[10]  N. Hacker,et al.  Loss of Secreted Frizzled-Related Protein 4 Correlates with an Aggressive Phenotype and Predicts Poor Outcome in Ovarian Cancer Patients , 2012, PloS one.

[11]  G. Moreno-Bueno,et al.  &bgr;-Catenin Expression Pattern, &bgr;-Catenin Gene Mutations, and Microsatellite Instability in Endometrioid Ovarian Carcinomas and Synchronous Endometrial Carcinomas , 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[12]  S. Groshen,et al.  Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Kuo,et al.  Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. , 2012, International journal of biochemistry and molecular biology.

[14]  M. Saegusa,et al.  Frequent nuclear β‐catenin accumulation and associated mutations in endometrioid‐type endometrial and ovarian carcinomas with squamous differentiation , 2001, The Journal of pathology.

[15]  C. Oshima,et al.  Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. , 2009, Oncology reports.

[16]  Hideki Yamamoto,et al.  Multiplicity of the interactions of Wnt proteins and their receptors. , 2007, Cellular signalling.

[17]  Li Zhao,et al.  Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.

[18]  S. Bernasconi,et al.  Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype , 2012, Cell cycle.

[19]  K. Nephew,et al.  Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide , 2012, Molecular Cancer Therapeutics.

[20]  J. Beatty,et al.  Role of bone marrow transplantation in 90Y antibody therapy of colon cancer xenografts in nude mice. , 1990, Cancer research.

[21]  M. Quinn,et al.  Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden , 2013, Molecular Cancer.

[22]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Ronald D. Alvarez,et al.  Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer , 2011, Clinical Cancer Research.

[24]  Yanli Jin,et al.  Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. , 2010, Cancer research.

[25]  W. Gianni,et al.  Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease. , 2010, Current cancer drug targets.

[26]  W. Birchmeier,et al.  Wnt signaling in stem and cancer stem cells. , 2013, Current opinion in cell biology.

[27]  S. Angers,et al.  Inhibition of Tankyrases Induces Axin Stabilization and Blocks Wnt Signalling in Breast Cancer Cells , 2012, PloS one.

[28]  M. Quinn,et al.  Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell‐like profile , 2011, Journal of cellular biochemistry.

[29]  M. Stack,et al.  Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment , 2011, The Biochemical journal.

[30]  S. Rai,et al.  MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines , 2011, Journal of ovarian research.

[31]  Wei Chen,et al.  Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. , 2011, Cancer research.

[32]  J. Palacios,et al.  Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. , 1998, Cancer research.

[33]  J. Palacios,et al.  Mutations in the β-Catenin Gene (CTNNB1) in Endometrioid Ovarian Carcinomas , 1998 .

[34]  J. Palacios,et al.  β-Catenin Expression Pattern in Stage I and II Ovarian Carcinomas : Relationship with β-Catenin Gene Mutations, Clinicopathological Features, and Clinical Outcome , 1999 .

[35]  K. Ding,et al.  Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells , 2012, Chinese journal of cancer.

[36]  J. Palacios,et al.  beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. , 1999, The American journal of pathology.

[37]  G. Chenevix-Trench,et al.  β‐Catenin mutation and expression analysis in ovarian cancer: Exon 3 mutations and nuclear translocation in 16% of endometrioid tumours , 1999, International journal of cancer.

[38]  Zijie Sun,et al.  Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. , 2006, Cancer letters.

[39]  S. Cannistra,et al.  Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Stack,et al.  Integrin Regulation of β-Catenin Signaling in Ovarian Carcinoma* , 2011, The Journal of Biological Chemistry.

[41]  P. Lochhead,et al.  Wnt signaling in the ovary: identification and compartmentalized expression of wnt-2, wnt-2b, and frizzled-4 mRNAs. , 2002, Endocrinology.

[42]  G. Piazza,et al.  Niclosamide Suppresses Cancer Cell Growth By Inducing Wnt Co-Receptor LRP6 Degradation and Inhibiting the Wnt/β-Catenin Pathway , 2011, PloS one.

[43]  Kathleen R. Cho,et al.  Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. , 2001, Cancer research.

[44]  S. Hewitt,et al.  Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of β-catenin in ovarian tumours , 2006, British Journal of Cancer.

[45]  A. Rajasekaran,et al.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. , 2006, Cancer research.

[46]  A. McMahon,et al.  Female development in mammals is regulated by Wnt-4 signalling , 1999, Nature.

[47]  M. Hung,et al.  beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. , 2003, Gynecologic oncology.

[48]  S. Ivy,et al.  Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways , 2011, Nature Reviews Clinical Oncology.

[49]  B. Monk,et al.  Wnt signaling in ovarian tumorigenesis , 2007, International Journal of Gynecologic Cancer.

[50]  L. Dubeau,et al.  The cell of origin of ovarian epithelial tumours. , 2008, The Lancet. Oncology.

[51]  Lilya V. Matyunina,et al.  Molecular profiling supports the role of epithelial-to-mesenchymal transition (EMT) in ovarian cancer metastasis , 2013, Journal of Ovarian Research.

[52]  Marina Vannucci,et al.  A systems biology approach reveals common metastatic pathways in osteosarcoma , 2012, BMC Systems Biology.

[53]  P. Carlsson,et al.  Wnt-signalling pathway in ovarian epithelial tumours: increased expression of β-catenin and GSK3β , 2003, British Journal of Cancer.

[54]  A. McMahon,et al.  Sexually dimorphic development of the mammalian reproductive tract requires Wnt-7a , 1998, Nature.

[55]  K. Hirasawa,et al.  Antisense Suppression of Pygopus2 Results in Growth Arrest of Epithelial Ovarian Cancer , 2006, Clinical Cancer Research.

[56]  Marc W. Kirschner,et al.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.

[57]  K. Brennan,et al.  Wnt Proteins Induce Dishevelled Phosphorylation via an LRP5/6- Independent Mechanism, Irrespective of Their Ability To Stabilize β-Catenin , 2004, Molecular and Cellular Biology.